Natraj Proteins Ltd. Corporate Filings & Announcements

Latest corporate announcements and filings from Natraj Proteins Ltd. on BSE

Load latest

Natraj Proteins Ltd.

29 Dec 2022

40.60

1.50%

SAST

NATRAJ PROTEINS LTD. - 530119 - Closure of Trading Window

BSE India

We would like to inform you that pursuant to SEBI (Prohibition of Insider Trading) Regulation, 2015 as amended from time to time and read with BSE circular No. LIST/COMP/01/2019-20 dated 2nd April, 2019, the window for trading in the shares of the Company shall remain close from 1st January, 2023 till completion of 48 hours after the declaration of the Quarterly and Nine Monthly Un-audited Standalone Financial Results for the Quarter and Nine Months ended on 31st December, 2022. All the Promoter and Promoter group, Directors, KMP's, Designated Persons/Employees, Connected Persons of the Company and their immediate relatives are advised not to deal in the shares of the Company either directly or indirectly during the aforesaid period. The date of meeting of the Board of Directors to approve the Quarterly and Nine Monthly Unaudited Standalone Financial Results of the Company for the Quarter and Nine Months ended on 31st December, 2022 shall be informed in due course.

pdf

Natraj Proteins Ltd.

28 Nov 2022

40.60

1.50%

Result

NATRAJ PROTEINS LTD. - 530119 - Submission Of Disclosure Under Regulation 23(9) Of SEBI (LODR) Regulations, …

BSE India

Pursuant to Regulation 23(9) of SEBI (LODR) Regulations, 2015 as amended from time to time, we are pleased to submit the disclosure of Statement of Related Party Transactions for the half year ended on 30th September, 2022. The same is also published on the Website of the Company www.natrajproteins.com. The Statement of Related Party Transactions will also be filed in XBRL mode within the stipulated time period.

pdf

Natraj Proteins Ltd.

14 Nov 2022

40.60

1.50%

Company Update

NATRAJ PROTEINS LTD. - 530119 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Pursuant to Regulation 30 read with Schedule III Part A(A) and in compliance of Regulation 47(1)(b) of SEBI (LODR) Regulations, 2015 regarding extract of Standalone Un-Audited Quarterly and Half Yearly Financial Results for the Quarter and Half Year ended on 30th September, 2022 was approved in 04/2022-23 Meeting of the Board of Directors held on Friday, 11th November, 2022 at 3:00 P.M. at the Registered Office of the Company. We herewith enclose the newspaper advertisement published on 12.11.2022 in Free Press Journal English edition and Chotha Sansar Hindi edition.

pdf

Natraj Proteins Ltd.

11 Nov 2022

40.60

1.50%

Company Update

NATRAJ PROTEINS LTD. - 530119 - Intimation Under Regulation 30(6) Of Securities And Exchange Board Of …

BSE India

In terms of Regulation 30 (6) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that Mr. Abhinandan Prajapati, has been appointed for the position of Chief Financial Officer, Key Managerial Personnel of the Company with effect from close of business hours on 11th November, 2022

pdf

Natraj Proteins Ltd.

11 Nov 2022

40.60

1.50%

Board Meeting

NATRAJ PROTEINS LTD. - 530119 - Board Meeting Outcome for Outcome Of The 4/2022-23 Board Meeting …

BSE India

Approval for appointment of Mr. Abhinandan Prajapati as the Chief Financial Officer of the company w.e.f. 11.11.2022

pdf

Natraj Proteins Ltd.

11 Nov 2022

40.60

1.50%

Result

NATRAJ PROTEINS LTD. - 530119 - Submission Of The Standalone Un-Audited Financial Results Alongwith The Statement …

BSE India

Pursuant to Regulation 33 of SEBI (LODR) Regulation, 2015 we are pleased to submit the following; (a) Standalone Unaudited Financial Results for the half year/quarter ended 30th September, 2022; (b) Standalone Limited Review Report by the Auditors for the half year/quarter ended 30th September, 2022; (c) Standalone Statement of Assets & Liabilities for the half year ended 30th September, 2022; (d) Standalone Statement of Cash flow for the half year ended 30th September, 2022.

pdf

Natraj Proteins Ltd.

02 Nov 2022

40.60

1.50%

Board Meeting

NATRAJ PROTEINS LTD. - 530119 - Board Meeting Intimation for Consideration And Approval Of The Standalone …

BSE India

NATRAJ PROTEINS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2022 ,inter alia, to consider and approve 1. Approval of the Standalone Un-Audited Financial Results of the Company for the Half year/ Quarter ended 30th September, 2022. 2. To take on Record the Limited Review Report by the Auditors for the Standalone Financial Results of the Company for the Half year/ Quarter ended 30th September, 2022. 3. Approval of the Standalone Un-Audited Statement of Assets and Liabilities for the half year ended on 30th September, 2022; and 4. Approval of the Standalone Un-Audited Statement of Cash Flow for the half year ended on 30th September, 2022.

pdf

Natraj Proteins Ltd.

19 Oct 2022, 06:04PM

40.60

1.50%

Corp. Note

NATRAJ PROTEINS LTD. - 530119 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / …

BSE India

Intimation regarding issuance of duplicate share certificates/Letter of Confirmation due to Loss of Share Certificates under Regulation 39(3) of SEBI (LODR) Regulations, 2015.

pdf

Natraj Proteins Ltd.

13 Oct 2022

40.60

1.50%

Corp. Note

NATRAJ PROTEINS LTD. - 530119 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / …

BSE India

Intimation regarding request for issuance of Letter of Confirmation due to Loss of Share Certificates under Regulation 39(3) of SEBI (LODR), Regulations, 2015.

pdf

Natraj Proteins Ltd.

07 Oct 2022

40.60

1.50%

Company Update

NATRAJ PROTEINS LTD. - 530119 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

BSE India

Certificate for Compliance of Regulation 74(5) of the SEBI (Depositaries and Participants) Regulation, 2018 (erstwhile Reg. 54 of SEBI (Depository and Participant) Regulations, 1996) for the quarter ended 30th September, 2022.

pdf

Is Natraj Proteins Ltd. worth buying?

26 Votes:

Buy 73.08%

Sell 7.69%

Hold 19.23%